Immuneering Reports First Patient Dosing with IMM-6-415 in the P-I/IIa Study for Treating Advanced Solid Tumors
Shots:
- Immuneering has dosed the first patient with IMM-6-415 in the P-I/IIa clinical evaluation for the treatment of advanced solid tumors associated with RAF or RAS mutations
- The P-I/IIa dose escalation and expansion study assesses the safety, tolerability, PK/PD characteristics as well as RP2D of IMM-6-415 (oral, BID) in the P-I part while the P-IIa part carries out RP2D evaluation in specific tumor arms for the treatment of patients with advanced RAF/RAS mutant solid tumors
- IMM-6-415 is a deep cyclic inhibitor (DCI) of the MAPK pathway that demonstrated RAF or RAS mutant tumor growth inhibition both as a monotx. and combination treatment in preclinical studies
Ref: Immuneering | Image: Immuneering
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
